SCHEMBL22097161

SCHEMBL22097161

c1ccc(-c2ccc(-c3nc(-c4ccccc4)nc(-c4ccc5c(c4)c4ccccc4c4cc6c(cc54)sc4ccccc46)n3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR3 P46089 1/20 0.40
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
PIM3 Q86V86 1/20 0.36
ATM Q13315 1/20 0.36
CYP1A2 P05177 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
LIMK1 P53667 2/20 0.35
NTSR1 P30989 1/20 0.34
PIK3CA P42336 1/20 0.34
PI4KA P42356 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
TNKS O95271 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096962 1.00 MAPT (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL18371746 0.99 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22097214 0.99 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL29747023 0.99 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22250007 0.94 MEN1 (0.39) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL18960978 0.94 GPR3 (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22097104 0.94 MEN1 (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24169294 0.93 PIM3 (0.43) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24169815 0.93 PIM3 (0.43) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24169547 0.93 PIM3 (0.43) MAPTALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236075-B2 Organic compound and organic electroluminescence device using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2022-02-01 US disclosed
US-20200190065-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2020-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236075-B2 Organic compound and organic electroluminescence device using the same ICMT, OR10J3, PIEZO1 MAPT 508/4885ALDH1A1 1010/4885HPGD 2478/4885
US-20200190065-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME ICMT, OR10J3, PIEZO1 MAPT 508/4885ALDH1A1 1010/4885HPGD 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.